Evidence map›Paper›PMID 32845256›Full record

ArticleDalton transactions (Cambridge, England : 2003)2020

Avobenzone incorporation in a diverse range of Ru(II) scaffolds produces potent potential antineoplastic agents.

Raphael T Ryan, Dmytro Havrylyuk, Kimberly C Stevens, L Henry Moore, Doo Young Kim, Jessica S Blackburn, David K Heidary, John P Selegue, Edith C Glazer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dalton transactions (Cambridge, England : 2003), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Raphael T RyanDepartment of Chemistry, University of Kentucky, 505 Rose Street, Lexington, KY 40506, USA. ec.glazer@uky.edu.
Dmytro Havrylyuk
Kimberly C Stevens
L Henry Moore
Doo Young Kim
Jessica S Blackburn
David K Heidary
John P Selegue
Edith C Glazer
University of Kentucky · US

Funding

The Phosphatase PRL3 as a MYC Target and Pro-Survival Oncogene in Acute Lymphoblastic LeukemiaR37CA227656 · NCI · UNIVERSITY OF KENTUCKY · PI BLACKBURN, JESSICA S. · 2018 to 2024
$2.4M
Harnessing Single Cell Technology to Define Self-Renewal in Normal and Malignant Stem CellsDP2CA228043 · NCI · UNIVERSITY OF KENTUCKY · PI BLACKBURN, JESSICA S. · 2017 to 2017
$2.3M
Light-responsive ruthenium compounds for applications in diseaseR01GM107586 · NIGMS · UNIVERSITY OF KENTUCKY · PI GLAZER, EDITH C · 2014 to 2019
$1.7M
NCI NIH HHS DP2 CA228043NCI NIH HHS R37 CA227656NIGMS NIH HHS R01 GM107586
6 · The paper itself

Abstract

Four structurally distinct classes of polypyridyl ruthenium complexes containing avobenzone exhibited low micromolar and submicromolar potencies in cancer cells, and were up to 273-fold more active than the parent ligand. Visible light irradiation enhanced the cytotoxicity of some complexes, making them promising candidates for combined chemo-photodynamic therapy.

Indexed as

Antineoplastic AgentsCell Line, TumorCoordination ComplexesHumansLigandsPhotochemotherapyPropiophenonesRutheniumStructure-Activity RelationshipAntineoplastic AgentsavobenzoneCoordination ComplexesLigandsPropiophenonesRuthenium

Identifiers

PMID32845256
PMCPMC8607750
OpenAlexW3081488863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.